+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a



Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a



Scandinavian Journal of Gastroenterology 34(2): 194-198



Background: Preliminary results from combination therapy with interferon-alpha and ribavirin (IFN/Rib) in patients with chronic hepatitis C have been promising, with up to 50% sustained hepatitis C virus (HCV) RNA response. The aim of this study was to investigate whether a sustained HCV RNA response could be obtained with combination therapy in patients who were non-reponders or relapsers after IFN treatment. Methods: In a multicenter study we randomized 53 HCV RNA-positive patients into 2 treatment groups. They all had biopsy-confirmed chronic hepatitis C, and all were recruited from a previous IFN study: 26 were previous non-responders and 27 responders with relapse. Group A received interferon-alpha2a, 4.5 MIU thrice weekly for 6 months, and group B received ribavirin, 1000-1200 mg/day, in combination with the same dose of interferon-alpha2a for 6 months. Median Knodell index was 5.0 in both groups. Genotype 1 was found in 24 (45%), type 2 in 3 (6%), and type 3 in 26 (49%). Results: Sustained clearance of HCV viremia 6 months after interferon-alpha2a treatment stop was obtained in 12 of 53 patients (23%): 6 of 27 in the IFN group (22%) and 6 of 26 (23%) in the IFN/Rib group (NS). Nine of 27 (33%) former responders with relapse, compared with 3 of 26 (12%) non-responders, obtained a sustained HCV RNA response (P = 0.054). In previous relapse patients sustained loss of viremia was more frequent in genotype 3 (50%) than in genotype 1 (11%) patients (P = 0.022). Conclusions: In a group of previous IFN-alpha2a-treated chronic HCV patients we obtained a similar sustained clearance of viremia when retreated either with IFN-alpha2a alone or with a combination of IFN-alpha2a and ribavirin for 6 months. Previous relapse patients with HCV genotype 3 obtained sustained loss of viremia significantly more often (50%) than type-1 patients (11%). Previous IFN responders with relapse responded better than previous non-responders.

(PDF emailed within 0-6 h: $19.90)

Accession: 011593703

Download citation: RISBibTeXText

PMID: 10192200

DOI: 10.1080/00365529950173087


Related references

A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy. Alimentary Pharmacology & Therapeutics 19(3): 339-347, 2004

Is immunological therapy useful in chronic hepatitis C virus infection? A randomized study of interferon alpha2a plus cimetidine versus interferon alpha2a plus placebo. Hepatology 32(4 Pt 2): 443A, October, 2000

A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. Alimentary Pharmacology & Therapeutics 24(7): 1079-1086, 2006

Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients. Intervirology 53(3): 146-153, 2010

Chronic hepatitis C treatment with pegilated interferon alpha2a and ribavirin in patients with HIV-infection. Terapevticheskii Arkhiv 79(11): 40-44, 2007

Chronic hepatitis C treatment with pegilated interferon alpha2a and ribavirin in patients with HIV-infection. Terapevticheskii Arkhiv 79(11): 40-44, 2008

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 49(6): 1847-1858, 2009

Bedeutung der immunochemotherapie fur das uberleben von patienten mit metastasiertem nierenzellkarzinom - Eine retrospektive studie der therapie-gruppen interferon-alpha2a/vinblastin vs. interferon-alpha2a/interleukin-2/5-fluorouracil. Urologe A 43(9): 1111-1119, 2004

Interferon alpha2a in combination with lamivudine in the treatment of patients with chronic HbeAg hepatitis B non-responders to interferon monotherapy. Journal of Hepatology 36(Supplement 1): 245, April, 2002

Treatment of chronic hepatitis C in naive patients with high-dose interferon-alpha2a induction therapy and two different ribavirin doses. Digestive and Liver Disease 36(5): 367-368, 2004

Prediction of nonSVR to therapy with pegylated interferon-alpha2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment. Journal of Viral Hepatitis 17(5): 345-351, 2010

Extracorporeal photopheresis alone and with interferon-alpha2a in chronic hepatitis C patients who failed previous interferon therapy. Digestive Diseases and Sciences 44(5): 1020-1026, 1999

Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b. Antiviral Therapy 13(4): 511-517, 2008